ABSTRACT
Objective:To evaluate the effects of the nadirs of neutrophils and lymphocytes during concurrent chemoradiotherapy (CCRT) on clinical prognosis of patients with cervical cancer, aiming to provide reference data for clinicians.Methods:Clinical data of FIGO (2018)Ⅰ B1-Ⅳ A cervical cancer patients treated with radical CCRT in the University of Hong Kong-Shenzhen Hospital, from January 2015 to September 2019 were analyzed. Routine blood test was performed weekly. The overall survival (OS) was calculated by Kaplan- Meier method and analyzed by log-rank test. Univariate and Multivariate prognostic analysis were performed by Cox proportional hazards model. Results:A total of 87 patients were included. The cutoff values of absolute neutrophil count nadir (ANC n) and absolute lymphocyte count nadir (ALC n) for predicting OS were determined by receiver operating characteristic curve. Compared with the ANC n of ≤2.14×10 9/L ( n=76), patients with the ANC n of > 2.14×10 9/L ( n=11) had lower 2-year OS rate (54.5% vs. 88.9%, P=0.035). Compared with ALC n of > 0.2×10 9/L ( n=49), patients with ALC n of ≤0.2×10 9/L ( n=38) obtained lower 2-year OS rate (75.3% vs. 90.8%, P=0.008). Multivariate analysis showed that ANC n (>2.14×10 9/L vs. ≤2.14×10 9/L)( HR=4.487, 95% CI: 1.404-14.344, P=0.011), ALC n (≤0.2×10 9/L vs. >0.2×10 9/L)( HR=5.814, 95% CI: 1.822-18.554, P=0.003), concurrent chemotherapy cycle (5-6 cycles vs. 0-4 cycles)( HR=0.204, 95% CI: 0.060-0.696, P=0.011) and the mean body radiation dose ( HR=1.296, 95% CI: 1.125-1.493, P<0.001) were significantly associated with OS. Patients with the ANC of > 5.19×10 9/L before CCRT were more likely to have ANC n of > 2.14×10 9/L during CCRT and those with the ALC of < 2.05×10 9/L before CCRT was more likely to have ALC n of ≤0.2×10 9/L during CCRT. Conclusions:Peripheral ANC n and ALC n during CCRT have different prognostic effects and influencing factors. Clinical prognosis of cervical cancer patients may be improved by closely monitoring routine blood parameters and optimizing treatment modality during CCRT.
ABSTRACT
Objective: To introduce the diagnosis and treatment of a case of male primary mediastinal choriocarcinoma, and to summarize the diagnosis and treatment of the disease by literature review. Methods: The diagnosis and treatment process of a male patient with primary mediastinal choriocarcinoma was reported. The clinical characteristics, diagnosis and treatment of 132 cases of primary mediastinal choriocarcinoma were retrospectively analyzed, in order to summarize the experience of diagnosis and treatment of this disease. Results: A 19-year-old male was admitted to hospital in September 2017 due to “chest pain and dyspnea for 1 week”. After 2 times of CT-guided mediastinal punctures, he was diagnosed with “choriocarcinoma”. After 8 times of chemotherapy and local radiotherapy for mediastinal and lung masses were completed in the hospital from October 2017 to March 2018, the response evaluation was partial remission. Following up to December 2018, the patient was generally in good condition, and no progression of tumor was observed; but he died in March 2019 due to suspected tumor recurrence. The literature review showed that the disease was rare in clinical practice, lacking of large-scale clinical studies and consensus on treatment options, so the median survival time of patients was generally short. Conclusion: Primary mediastinal choriocarcinoma in male is a rare disease that lacks specific clinical features. The treatment mainly relies on the comprehensive treatment including surgery, chemotherapy and radiotherapy, but the disease progresses rapidly with poor prognosis.